- Home
- CAMT vs ACAD Comparison
CAMT vs ACAD Comparison
Compare CAMT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAMT
- ACAD
- Stock Information
- Founded
- CAMT 1987
- ACAD 1993
- Country
- CAMT Israel
- ACAD United States
- Employees
- CAMT N/A
- ACAD N/A
- Industry
- CAMT Electronic Components
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- CAMT Technology
- ACAD Health Care
- Exchange
- CAMT Nasdaq
- ACAD Nasdaq
- Market Cap
- CAMT 4.3B
- ACAD 3.9B
- IPO Year
- CAMT 2000
- ACAD 2004
- Fundamental
- Price
- CAMT $105.72
- ACAD $25.17
- Analyst Decision
- CAMT Strong Buy
- ACAD Buy
- Analyst Count
- CAMT 11
- ACAD 21
- Target Price
- CAMT $116.36
- ACAD $29.00
- AVG Volume (30 Days)
- CAMT 514.1K
- ACAD 1.6M
- Earning Date
- CAMT 11-10-2025
- ACAD 11-05-2025
- Dividend Yield
- CAMT 1.27%
- ACAD N/A
- EPS Growth
- CAMT N/A
- ACAD 98.53
- EPS
- CAMT 1.01
- ACAD 1.54
- Revenue
- CAMT $485,241,000.00
- ACAD $1,047,118,000.00
- Revenue This Year
- CAMT $17.39
- ACAD $14.12
- Revenue Next Year
- CAMT $8.22
- ACAD $11.80
- P/E Ratio
- CAMT $102.10
- ACAD $15.82
- Revenue Growth
- CAMT 21.12
- ACAD 12.69
- 52 Week Low
- CAMT $47.41
- ACAD $13.40
- 52 Week High
- CAMT $129.41
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- CAMT 48.85
- ACAD 66.30
- Support Level
- CAMT $91.91
- ACAD $22.81
- Resistance Level
- CAMT $104.34
- ACAD $23.98
- Average True Range (ATR)
- CAMT 5.39
- ACAD 0.97
- MACD
- CAMT -0.31
- ACAD 0.15
- Stochastic Oscillator
- CAMT 49.71
- ACAD 100.00
About CAMT Camtek Ltd.
Camtek Ltd is engaged in the manufacturing of metrology and inspection equipment and software solutions for the semiconductor industry. Its systems inspect wafers for various semiconductor market segments, including Advanced Packaging, Heterogenous Integration (HI), Compound Semiconductors, Memory, and foundries among others. Geographically, it derives maximum revenue from China followed by Asia Pacific, Korea, United States, and Europe. The company's products and services include Surface Inspection, Bump Inspection and Metrology, and others.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.